Ascletis Pharma (SEHK:1672) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

1672 Overzicht aandelen

Ascletis Pharma Inc. is een biotechnologiebedrijf dat zich bezighoudt met onderzoek en ontwikkeling, productie, marketing en verkoop van farmaceutische producten op het Chinese vasteland.

Over het bedrijf

1672 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen zinvolle omzet ( CN¥10M )

Volatiele aandelenkoers in de afgelopen 3 maanden

Ascletis Pharma Inc. Concurrenten

Brii Biosciences

SEHK:2137

HK$1.1b

Wuhan YZY Biopharma

SEHK:2496

HK$1.3b

Immunotech Biopharm

SEHK:6978

HK$1.4b

Sunho Biologics

SEHK:2898

HK$789.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ascletis Pharma
Historische aandelenkoersen
Huidige aandelenkoers	HK$1.37
52 Week Hoogtepunt	HK$2.05
52 Week Laag	HK$0.76
Bèta	0.69
11 maand verandering	37.00%
3 maanden verandering	47.31%
1 Jaar Verandering	-28.65%
33 jaar verandering	-49.82%
5 jaar verandering	-54.33%
Verandering sinds IPO	-90.21%

Recent nieuws en updates

Recent updates

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Dec 19

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Aug 23

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Nov 03

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Oct 13

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Aug 24

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

May 19

Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts

Mar 27

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Feb 08

Rendement voor aandeelhouders

	1672	HK Biotechs	HK Markt
7D	25.7%	13.9%	8.7%
1Y	-28.6%	5.1%	25.5%

Rendement versus industrie: 1672 presteerde slechter dan de Hong Kong Biotechs -sector, die het afgelopen jaar een rendement van -1.6 % opleverde.

Rendement versus markt: 1672 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 16.1 % opleverde.

Prijsvolatiliteit

Is 1672's price volatile compared to industry and market?
1672 volatility
1672 Average Weekly Movement	11.3%
Biotechs Industry Average Movement	8.8%
Market Average Movement	7.6%
10% most volatile stocks in HK Market	16.6%
10% least volatile stocks in HK Market	3.8%

Stabiele aandelenkoers: De aandelenkoers van 1672 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van 1672 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Hong Kong.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	219	Jinzi Jason Wu	www.ascletis.com

Ascletis Pharma Inc., een biotechnologiebedrijf, houdt zich bezig met onderzoek en ontwikkeling, productie, marketing en verkoop van farmaceutische producten op het Chinese vasteland. Het bedrijf biedt een Ritonavir-tablet en ASCLEVIR en GANOVO voor de behandeling van het hepatitis C-virus. Het ontwikkelt ook ASC22 voor de behandeling van CHB en HIV functionele genezing; ASC10 voor respiratoir syncytievirus; ASC10 en ASC11 voor de behandeling van COVID-19; ASC40, ASC41, ASC42, ASC43F FDC voor niet-alcoholische steatohepatitis; en ASC42 voor de behandeling van primaire biliaire cholangitis.

Ascletis Pharma Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Ascletis Pharma zich tot de beurswaarde?
1672 fundamentele statistieken
Marktkapitalisatie	HK$1.36b
Inkomsten(TTM)	-HK$284.66m
Inkomsten(TTM)	HK$11.11m

122.0x

P/S-verhouding

-4.8x

Koers/Winstverhouding

Is 1672 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
1672 resultatenrekening (TTM)
Inkomsten	CN¥10.09m
Kosten van inkomsten	CN¥22.72m
Brutowinst	-CN¥12.63m
Overige uitgaven	CN¥245.84m
Inkomsten	-CN¥258.47m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.26
Brutomarge	-125.17%
Nettowinstmarge	-2,561.68%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 1672 op de lange termijn?

Bekijk historische prestaties en vergelijking

1672 Overzicht aandelen

Beloningen

Risicoanalyse

Ascletis Pharma Inc. Concurrenten

SEHK:2137

HK$1.1b

SEHK:2496

HK$1.3b

SEHK:6978

HK$1.4b

SEHK:2898

HK$789.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

New minor risk - Revenue size

New minor risk - Share price stability

Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024

Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024

Ascletis Pharma Inc., Annual General Meeting, May 23, 2024

Recent updates

Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

New minor risk - Revenue size

New minor risk - Share price stability

Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024

Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024

Ascletis Pharma Inc., Annual General Meeting, May 23, 2024

Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

First half 2023 earnings: EPS exceeds analyst expectations

Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Consensus revenue estimates decrease by 19%, EPS upgraded

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022)

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis

New minor risk - Profitability

Consensus revenue estimates decrease by 22%, EPS upgraded

Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023

Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date moved forward to 2023

Consensus revenue estimates decrease by 12%

Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2023

Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa

Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc

Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19

Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne

Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA

Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA

Insufficient new directors

Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

Consensus revenue estimates fall by 19%

Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22

Consensus revenue estimates fall by 13%

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

First half 2022 earnings released: CN¥0.081 loss per share (vs CN¥0.10 loss in 1H 2021)